MOTHERISK ROUNDS: The Use of Antidepressants in Pregnancy: Focus on Maternal Risks

Yifat Gadot, Gideon Koren

Research output: Contribution to journalArticlepeer-review

Abstract

Studies have consistently reported a decrease in the use of antidepressants during pregnancy compared with the pre-pregnancy period. Multiple recent studies have focused on the potential fetal risks of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), with very little attention paid to maternal risks. The maternal risks of these medications are the focus of this review.Untreated depression is associated with increased risks of maternal morbidity, both somatic and psychiatric. In contrast, use of antidepressants has been associated with increased risks of hypertension, preeclampsia, and bleeding. In this review we present the evidence for maternal risks in an attempt to develop a risk-benefit ratio.

Original languageEnglish
Pages (from-to)56-63
Number of pages8
JournalJournal of Obstetrics and Gynaecology Canada
Volume37
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Keywords

  • Depression
  • Pregnancy
  • Risk
  • SNRI
  • SSRI
  • Selective norepinephrine reuptake inhibitor
  • Selective serotonin reuptake inhibitor

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'MOTHERISK ROUNDS: The Use of Antidepressants in Pregnancy: Focus on Maternal Risks'. Together they form a unique fingerprint.

Cite this